Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Account Payables: 2019-2024

Historic Change in Account Payables for Day One Biopharmaceuticals (DAWN) over the last 6 years, with Dec 2024 value amounting to $686,000.

  • Day One Biopharmaceuticals' Change in Account Payables rose 120.08% to $688,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 838.24%. This contributed to the annual value of $686,000 for FY2024, which is 70.38% down from last year.
  • As of FY2024, Day One Biopharmaceuticals' Change in Account Payables stood at $686,000, which was down 70.38% from $2.3 million recorded in FY2023.
  • Day One Biopharmaceuticals' Change in Account Payables' 5-year high stood at $2.3 million during FY2023, with a 5-year trough of -$1.5 million in FY2022.
  • Its 3-year average for Change in Account Payables is $506,000, with a median of $686,000 in 2024.
  • In the last 5 years, Day One Biopharmaceuticals' Change in Account Payables skyrocketed by 1,068.18% in 2021 and then tumbled by 196.24% in 2022.
  • Yearly analysis of 5 years shows Day One Biopharmaceuticals' Change in Account Payables stood at $132,000 in 2020, then surged by 1,068.18% to $1.5 million in 2021, then plummeted by 196.24% to -$1.5 million in 2022, then skyrocketed by 256.06% to $2.3 million in 2023, then crashed by 70.38% to $686,000 in 2024.